RKIP expression has been reported to be lost or reduced in prostate cancer, breast cancer, liver cancer and other malignant tumors because its role in inhibiting the RAS/RAF/MEK/ERK signaling pathway [21], which is activated in over 90 % of HCCs. This evidence concerns the gene MAP2K7 and prostate cancer.